Related references
Note: Only part of the references are listed.Metal complexes in medicine with a focus on enzyme inhibition
Chi-Ming Che et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2010)
Osmium(II)-versus ruthenium(II)-arene carbohydrate-based anticancer compounds: similarities and differences
Muhammad Hanif et al.
DALTON TRANSACTIONS (2010)
In vivo tumour and metastasis reduction and in vitro effects on invasion assays of the ruthenium RM175 and osmium AFAP51 organometallics in the mammary cancer model
A. Bergamo et al.
JOURNAL OF INORGANIC BIOCHEMISTRY (2010)
Cytotoxicity, Hydrophobicity, Uptake, and Distribution of Osmium(II) Anticancer Complexes in Ovarian Cancer Cells
Sabine H. van Rijt et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Thioredoxin reductase: A target for gold compounds acting as potential anticancer drugs
Alberto Bindoli et al.
COORDINATION CHEMISTRY REVIEWS (2009)
The anti-cancer properties of gold(III) compounds with dianionic porphyrin and tetradentate ligands
Raymond Wai-Yin Sun et al.
COORDINATION CHEMISTRY REVIEWS (2009)
The tumor proteasome as a novel target for gold(III) complexes: Implications for breast cancer therapy
Vesna Milacic et al.
COORDINATION CHEMISTRY REVIEWS (2009)
Dual anti-angiogenic and cytotoxic properties of ruthenium(III) complexes containing pyrazolato and/or pyrazole ligands
Raymond Wai-Yin Sun et al.
DALTON TRANSACTIONS (2009)
Non-traditional platinum compounds for improved accumulation, oral bioavailability, and tumor targeting
Katherine S. Lovejoy et al.
DALTON TRANSACTIONS (2009)
[OsIVCl5(Hazole)]- Complexes: Synthesis, Structure, Spectroscopic Properties, and Anti proliferative Activity
Gabriel E. Buechel et al.
INORGANIC CHEMISTRY (2009)
New trends for metal complexes with anticancer activity
Pieter C. A. Bruijnincx et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2008)
DNA interactions of monofunctional organometallic osmium(II) antitumor complexes in cell-free media
Hana Kostrhunova et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
The resurgence of platinum-based cancer chemotherapy
Lloyd Kelland
NATURE REVIEWS CANCER (2007)
Using coordination chemistry to design new medicines
Luca Ronconi et al.
COORDINATION CHEMISTRY REVIEWS (2007)
From bench to bedside -: preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A)
Christian G. Hartinger et al.
JOURNAL OF INORGANIC BIOCHEMISTRY (2006)
Tuning the reactivity of osmium(II) and ruthenium(II) arene complexes under physiological conditions
AFA Peacock et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2006)
Ruthenium complexes as anticancer agents
I Kostova
CURRENT MEDICINAL CHEMISTRY (2006)
G-quartets 40 years later: From 5 '-GMP to molecular biology and supramolecular chemistry
JT Davis
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2004)
Ruthenium antimetastatic agents
E Alessio et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2004)
The remarkable reactivity of high oxidation state ruthenium and osmium polypyridyl complexes
TJ Meyer et al.
INORGANIC CHEMISTRY (2003)
Biological inorganic chemistry at the beginning of the 21st century
HB Gray
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Recent developments in the field of tumor-inhibiting metal complexes
M Galanski et al.
CURRENT PHARMACEUTICAL DESIGN (2003)
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer
JH Schiller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Facile nucleophilic addition to salophen coordinated to nitridoosmium(VI)
SM Chiu et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2001)
Share Paper
